Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Placebo-Controlled, Phase 2 Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)

NCT04388826 is registered in ClinicalTrials.gov with Veru Inc. as lead sponsor.

NCT NCT04388826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04388826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Placebo-Controlled, Phase 2 Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)
Lead sponsor
Veru Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 18, 2020
Completion date
August 13, 2021
Enrollment
39 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory distress syndrome, adult